Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Optical Workings: Specialists Must Communicate to Treat Eye Disease

Richard Quinn  |  May 19, 2017

In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…

Rheumatologist-Nobel Laureate Dr. Baruch (Barry) Blumberg Deserves Recognition

Philip L. Cohen, MD  |  May 18, 2017

I read with pleasure the March 2017 Rheuminations (written by Simon M. Helfgott, MD), but wanted to make a small emendation. There is one other rheumatologist–Nobel Laureate besides Philip Hench. Baruch (Barry) Blumberg (1925–2011) was a bona fide rheumatologist who trained in the mid-1950s with the renowned Charles Ragan at Columbia-Presbyterian Medical Center in New…

Trainees Discuss Pros, Cons of Rheumatology Residency Rotation

Katarzyna Gilek-Seibert, MD, with Anais Ovalle, MD, Elias Jabbour, MD, Heather Ferri, DO, & Gabrielle Thottam, MD  |  May 18, 2017

One day not too long ago, right smack in the middle of Thanksgiving and Christmas, I was sitting at the roundtable of our conference room, also known as the solarium due to its sunny disposition. The spirit was high, and we all felt like we could bring some joy to the clinic that day. I…

ARHP President Dr. Afton L. Hassett’s Rise from Annual Meeting Attendee to Leadership Role

Erin Latimer Meadows  |  May 18, 2017

Current ARHP President Afton L. Hassett, PsyD—a clinical psychologist and an associate research scientist in the Department of Anesthesiology at the University of Michigan—attended her first ACR/ARHP Annual Meeting in 1999. Dr. Hassett submitted an abstract to the meeting describing her dissertation research exploring the role of pain and depression in rheumatoid arthritis and fibromyalgia. It…

Rocketclips, Inc./shutterstock.com

Tips for Managing Young Adult Rheumatology Patients

Gregory Taylor, MSW, RCSW  |  May 18, 2017

Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…

Demand for Arthritis Care in America Outstrips Supply of Practicing Rheumatologists

Sharad Lakhanpal, MBBS, MD  |  May 18, 2017

May is National Arthritis Awareness Month. The ACR is committed to ensuring that arthritis and rheumatologic diseases are at the forefront of public awareness—and that better, safer treatments reach Americans in need. Fortunately, the federal government is also doing its part and has just released a major report on the national impact of arthritis. A…

How Tuberculosis Has Shaped Medicine and Society

Simon M. Helfgott, MD  |  May 17, 2017

Pathologists are legendary for blending their work product with the culinary arts. Through the years, their use of delectable foods as descriptors has created a clever way to indelibly link in the minds of clinicians the histopathologic observations of disease with an assortment of these tasty foods: There is the depiction of an apple green…

Lightspring/shutterstock.com

The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

Dana Direnzo, MD, Ami A. Shah, MD, MHS, Clifton O. Bingham III, MD, & Laura C. Cappelli, MD, MHS  |  May 17, 2017

A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

BYUNG H. BAN, DO

Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

Byung H. Ban, DO, Jayne L. Crowe, MD, & Robert M. Graham, MD  |  May 17, 2017

Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…

Four-Week Methotrexate Break Improves Flu Shot Response in RA Patients

Reuters Staff  |  May 17, 2017

NEW YORK (Reuters Health)—Temporarily withholding methotrexate (MTX) can improve the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA), according to a new randomized clinical trial. Response was strongest in patients who discontinued MTX for two weeks before and two weeks after receiving the flu shot, Dr. Eun Bong Lee of Seoul National…

  • « Previous Page
  • 1
  • …
  • 426
  • 427
  • 428
  • 429
  • 430
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences